Your browser doesn't support javascript.
Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS-CoV-2.
Cui, Yu; Hu, Caixia; Cheng, Yi; Han, Xiaomei; Wang, Wenqing.
  • Cui Y; Department of Dermatology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, P.R. China.
  • Hu C; Department of Dermatology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, P.R. China.
  • Cheng Y; Department of Dermatology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, P.R. China.
  • Han X; Department of Dermatology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, P.R. China.
  • Wang W; Department of Dermatology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, P.R. China.
Int J Dermatol ; 61(2): 252-256, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1406554
ABSTRACT
Bullous pemphigoid (BP) patients were vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection because they have similar risk factors, so we should pay attention to patients with BP during the epidemic of coronavirus disease-19 (COVID-19). As far as treatment is concerned, many strategies for BP were changed during the epidemic. Plasmapheresis not only has been included in the guidelines for BP but also has been used successfully to rescue COVID-19 patients, especially in severe cases. Therefore, it is a feasible choice for BP patients, especially for refractory BP patients, infected with SARS-CoV-2. Apart from these, we have reviewed some points for attention during the plasmapheresis session.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pemphigoid, Bullous / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Int J Dermatol Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pemphigoid, Bullous / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Int J Dermatol Year: 2022 Document Type: Article